Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
J Surg Oncol. 2023 Mar;127(3):374-384. doi: 10.1002/jso.27116. Epub 2022 Oct 4.
Heterogeneity in hepatocellular carcinoma (HCC) still exists within the Barcelona clinic liver cancer (BCLC) subcategories. We developed a simple model to better discriminate and predict prognosis following resection.
Patients who underwent curative-intent resection for HCC were identified from a multi-institutional database. Predictive factors of survival were identified to develop TAC (tumor burden score [TBS], alpha-fetoprotein [AFP], Child-Pugh CP]) score.
Among 1435 patients, median TBS was 5.1 (interquartile range [IQR]: 3.2-8.1), median AFP was 18.3 ng/ml (IQR 4.0-362.5), and 1391 (96.9%) patients were classified as CP-A. Factors associated with overall survival (OS) included TBS (low: referent; medium: HR 2.26, 95% CI: 1.73-2.96; high: HR = 3.35, 95% CI: 2.22-5.07), AFP (<400 ng/ml: referent; >400 ng/ml: HR = 1.56, 95% CI: 1.27-1.92), and CP (A: referent; B: HR = 1.81, 95% CI: 1.12-2.92) (all p < 0.05). A simplified risk score demonstrated superior concordance index, Akaike information criteria, homogeneity, and area under the curve versus BCLC (0.620 vs. 0.541; 5484.655 vs. 5536.454; 60.099 vs. 16.194; 0.62 vs. 0.55, respectively), and further stratified patients within BCLC groups relative to OS (BCLC 0, very low: 86.8%, low: 47.8%) (BCLC A, very low: 79.7%, low: 68.1%, medium: 52.5%, high: 35.6%) (BCLC B, low: 59.8%, medium: 43.7%, high: N/A).
TAC is a simple, holistic score that consistently outperformed BCLC relative to discrimination power and prognostication following resection of HCC.
在巴塞罗那临床肝癌(BCLC)亚类中,肝细胞癌(HCC)仍然存在异质性。我们开发了一种简单的模型,以更好地区分和预测手术后的预后。
从多机构数据库中确定接受根治性切除 HCC 的患者。确定生存预测因素以开发 TAC(肿瘤负担评分[TBS]、甲胎蛋白[AFP]、Child-Pugh CP])评分。
在 1435 名患者中,中位 TBS 为 5.1(四分位距[IQR]:3.2-8.1),中位 AFP 为 18.3ng/ml(IQR 4.0-362.5),1391(96.9%)名患者被归类为 CP-A。与总生存(OS)相关的因素包括 TBS(低:参照;中:HR 2.26,95%CI:1.73-2.96;高:HR=3.35,95%CI:2.22-5.07)、AFP(<400ng/ml:参照;>400ng/ml:HR=1.56,95%CI:1.27-1.92)和 CP(A:参照;B:HR=1.81,95%CI:1.12-2.92)(均 p<0.05)。简化风险评分显示出更高的一致性指数、Akaike 信息准则、同质性和曲线下面积,优于 BCLC(0.620 与 0.541;5484.655 与 5536.454;60.099 与 16.194;0.62 与 0.55),并进一步分层了 BCLC 组内的患者相对于 OS(BCLC 0,极低:86.8%,低:47.8%)(BCLC A,极低:79.7%,低:68.1%,中:52.5%,高:35.6%)(BCLC B,低:59.8%,中:43.7%,高:无)。
TAC 是一种简单的整体评分,与 HCC 切除后的区分能力和预后相比,始终优于 BCLC。